|
Sumatriptan/naproxen sodium is a medication manufactured under the trade name Treximet (formerly known as Trexima) by GlaxoSmithKline and POZEN Pharmaceutical Development Company for the treatment of migraines.〔http://www.treximet.com/〕 ==Active ingredients== It combines 85 mg of sumatriptan (as the succinate), a selective 5-hydroxytryptamine1 (5-HT1) receptor subtype agonist and 500 mg of naproxen sodium, a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs), in one tablet.〔http://www.gsk.com/media/pressreleases/2008/2008_us_pressrelease_10034.htm〕〔http://www.treximet.com/about/migraine-pain-relief.html〕 This drug has a unique RT formulation that allows for the rapid disintegration of the sumatriptan, but it does not affect the disintegration of the naproxen sodium component. It targets nerves and blood vessels believed to trigger a migraine and relieves the inflammation that can cause migraine pain. In clinical trials, Treximet provided a significantly greater percentage of patients migraine pain relief at two hours compared to sumatriptan 85 mg or naproxen sodium 500 mg alone. In addition, Treximet provided more patients sustained migraine pain relief from two to 24 hours compared to the individual components. Sumatriptan is also available in the United States as an inexpensive generic prescription medicine, while naproxen is also inexpensive and over the counter. Many doctors and pharmacists saw the addition of a simple over the counter pain reliever to sumatriptan, and the subsequent marketing of Treximet as a "new" product, with a price of over $200 for 9 tablets, as a cynical ploy by GlaxoSmithKline to continue making brand-name profits when its patent for sumatriptan expired. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Sumatriptan/naproxen sodium」の詳細全文を読む スポンサード リンク
|